New Study Seeks Better Outcomes for Kidney Cancer
A new clinical trial at the Ohio State University Medical Centerâ€™s James Cancer Hospital and Solove Research Institute will investigate the safety and toxicity of a new combination of drugs for treating kidney cancer.
The phase-I study combines high-dose interleukin-2 with the drug sorafenibterm and will enroll up to 24 patients.
Interleukin-2 is an immunotherapy drug that recruits the patientâ€™s immune system to kill cancer cells. Four to 6 percent of patients with advanced kidney cancer who are treated with interleukin-2 will achieve a complete remission that may last for more than 15 years, Monk says.
â€œRight now we donâ€™t know why some patients have a complete response to the drug, or how to predict which patients will experience it,â€ says Dr. Paul Monk, who along with Dr. Thomas Olencki of Ohio Stateâ€™s Comprehensive Cancer Center, is leading the study.
Sorafenib, which is commonly marketed as Nexavartermterm, was approved in December 2005 by the U.S. Food and Drug Administration for treating advanced kidney cancer. The oral drug slows the disease progression in more than 60 percent of patients with advanced kidney cancer, Monk says.
â€œWe want to learn whether combining these two drugs will provide more benefit to more patients,â€ Monk says.